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Abstract—Left ventricular assist devices (LVADs) are an in-
creasingly common therapy for patients with advanced heart
failure. However, implantation of the LVAD increases the risk
of stroke, infection, bleeding, and other serious adverse events
(AEs). Most post-LVAD AEs studies have focused on individual
AEs in isolation, neglecting the possible interrelation, or causality
between AEs. This study is the first to conduct an exploratory
analysis to discover common sequential chains of AEs following
LVAD implantation that are correlated with important clinical
outcomes. This analysis was derived from 58,575 recorded AEs
for 13,192 patients in International Registry for Mechanical
Circulatory Support (INTERMACS) who received a continuous-
flow LVAD between 2006 and 2015. The pattern mining pro-
cedure involved three main steps: (1) creating a bank of AE
sequences by converting the AEs for each patient into a single,
chronologically sequenced record, (2) grouping patients with
similar AE sequences using hierarchical clustering, and (3)
extracting temporal chains of AEs for each group of patients
using Markov modeling. The mined results indicate the existence
of seven groups of sequential chains of AEs, characterized by
common types of AEs that occurred in a unique order. The
groups were identified as: GRP1: Recurrent bleeding, GRP2:
Trajectory of device malfunction & explant, GRP3: Infection,
GRP4: Trajectories to transplant, GRP5: Cardiac arrhythmia,
GRP6: Trajectory of neurological dysfunction & death, and
GRP7: Trajectory of respiratory failure, renal dysfunction &
death. These patterns of sequential post-LVAD AEs disclose
potential interdependence between AEs and may aid prediction,
and prevention, of subsequent AEs in future studies.
Keywords: LVAD, sequential adverse events, hierarchical clus-
tering, Markov modeling.
I. INTRODUCTION
PATIENTS with advanced congestive heart failure (CHF)do not respond to traditional therapies like medical treat-
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Fig. 1: Illustration of HeartMate 3 LVAD from Thoratec
Corporation [1]. LVAD is a blood pump that is connected to
external components out of the body, including a controller
and power sources worn by patients, by a driveline.
ment and symptom management. Heart transplantation is con-
sidered the gold standard treatment for eligible patients with
advanced CHF but is severely limited by donor availability. It
was performed for only 2000-2500 eligible patients per year in
the US (half of the number of candidates added to the wait list
every year) [2]. Therefore, there has been an increasing need
to provide advanced CHF patients with alternative treatment
options,such as left ventricular assist devices (LVAD). The
LVAD is a pump that augments the flow of blood from the
left ventricle of the heart, as shown in Fig. 1.
In 2005, the National Institutes of Health (NIH) established
INTERMACS, which is currently the nation-wide database of
longitudinal data for mechanical assist devices with data from
>20,000 patients and >180 hospitals over the past decade
[3]. Based on the INTERMACS 2017 annual report, overall
1-year and 2- year patient survival rates were 81% and 70%,
respectively [3]. It also reported an enhanced patient quality
of life in the first 3 months after LVAD implantation that
lasted for at least 24 months [3]. Yet, INTERMACS reported
several risks of recurrent adverse events (AEs) following
LVAD implantation including bleeding, infection, cardiac ar-
rhythmia, stroke, and respiratory failure [3]. For 17,632 LVAD
patients between 2008- 2016, bleeding and infection were
the most frequent AEs, especially in the first 3 months post-
LVAD with rate (events per 100 patient-months) of 16.24 and
13.63, respectively. More importantly, subsequent survival is
impacted by the incidence of major AEs during the first 3
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2months post-LVAD [3].
There have been numerous clinical studies in recent years
focusing on the incidence, prevalence, and risk factors of post-
LVAD AE’s [5]–[16]. Most studies emphasized one type of
major AE like bleeding [6,7,9,13], infection [10,15]–[18], and
stroke [5,11,12,14,19,20]. Some studies investigated AEs of
one specific type of LVAD pump [8,9,14,16], while others
compared AEs between different types of pumps [5]–[7,17].
Some studies underlined the difference between the AEs of
LVAD as short-term versus long-term therapy [14,16]. There
have been also few studies investigated data-driven techniques
for AEs prediction including applying Bayesian model to pre-
dict the right heart failure or survival after LVAD [21,22] and
developing decision support system for patients management
after LVAD [23].
Although these studies provide many valuable clinical as-
pects of AEs, they suffer from major limitations. Some of
the results from these studies cannot be generalized as they
were case studies or based on one hospital with low numbers
of patients, usually a few hundred patient, compared with
thousands of patients in INTERMACS. Furthermore, most
were clinical studies that focused on traditional statistical
methods such as multivariable Cox-Regression Models to
establish hazard ratios, odds ratios, and event rates. No study
has implemented modern data mining techniques to model
patterns of post-LVAD AEs. Some are cross sectional studies
based on data at a specific point in time after LVAD implanta-
tion and therefore do not consider the transitions between AEs
over duration after LVAD implant. In addition, these studies
treated each type of AE as a separate event, neglecting the
possible interrelation or bootstrapping between AEs. LVAD-
associated AE rarely occur in isolation. This is due to the
causes of events being closely related. For example, a single
gastrointestinal (GI) bleed is often followed by more GI
bleeds, as the introduction of the continuous flow LVAD can
lead to von Willebrand factor dysfunction and arteriovenous
malformations [13]. Similarly, bleeding and stroke can occur
one after the other in LVAD patients due to issues finding the
right balance of anticoagulation [24]. No research has studied
the pattern of transition between AEs to answer questions such
as, “Which AEs occur commonly in a specific temporal order
after LVAD implantation?”.
A patient’s post-LVAD AEs can be represented as a tem-
poral sequence in which each AE is considered a unique
element connected to other elements in a sequence to identify
the transitions between AEs. Data from a large number of
patients’ histories of temporal AEs could be summarized and
visualized as a set of temporal sequences of AEs and then
patterns within the AE sequences could be extracted using
data mining techniques. Several recent studies have applied
various temporal mining techniques, such as Markov models
and Heuristics models, to extract recurring patterns from longi-
tudinal healthcare data [25]–[33]. These studies have identified
possible relativity and association between clinical variables
such as medical interventions, diagnoses, and treatments [25]–
[33].
To the best of our knowledge, this study is the first attempt
to explore and model sequential patterns of post-LVAD AEs
and specifically differentiate distinct groups of patients based
on their sequences of AEs. The overall approach for this study
is motivated by the methodology introduced by Zhang, et al.
et al. [4,34] and has three main steps, as shown in Fig. 2.
First, selected data from INTERMACS were transferred into
sequences of AEs for each patient through multiple prepro-
cessing tasks. Next, patients’ AE sequences were clustered into
groups with similar sequences using hierarchical clustering.
Lastly, patterns of chains of transitions between AEs for each
group were extracted using Markov Modeling. The results
of this study provide valuable real-world insights about post-
LVAD AEs patterns, which clinicians can use to make more
informed treatment and management decisions to improve
clinical outcomes of LVADs.
II. METHODOLOGY
A. Data pre-processing
1) INTERMACS data selection and pre-processing: This
study included 58,575 recorded AEs of 13,192 patients (me-
dian age of 50-59; 10,333 male vs. 2,859 female;) with
advanced heart failure who received a continuous flow LVAD
between 2006 to 2015, extracted from INTERMACS. It should
be noted that the incidence of heart failure is significantly
higher in men than women at all ages [35]. For patients with
multiple device implants, AEs after the first LVAD explant are
excluded as patients with multiple subsequent LVAD devices
are clinically treated differently.
Final outcomes, such as death, explant, and transplant, were
included as the last elements in the sequences of AEs. For the
subset of patients who received a right-ventricular assist device
(RVAD), the explant of that device was named to “REXP”.
For the visualization of the results, each type of AE and final
outcomes were color coded, as shown in Fig. 3.
2) Forming patients’ sequences: The sequence of AEs for
each patient was identified and unified as a single record. A
sequence for jth patient (P j) can be presented as follow:
Pj : AE1 → AE2 → .....→ AEi (1)
Where:
AE1 : First adverse event
...
AEi : ith adverse event
As INTERMACS provided no information related to the
order of concurrent AEs (negligible percent of AEs), they were
alphabetically ordered in patients’ sequences.
A consequence of the large number of event types (15) is the
possibility of a large number of sparse patterns. For example,
if we only considered sequences of length = 3, there would be
2,940 (14×14×15; “Death” could be considered for only the
last element) possible combinations. To overcome this issue,
hierarchical clustering was used to divide the space of patients’
sequences into more dense sub-spaces that represent patients
with relatively similar sequences which would therefore be
more amenable to pattern mining.
3Fig. 2: General work-flow: 1. Data preprocessing:Forming patients’ sequences. 2. Hierarchical clustering:cluster patients into
groups of patients with high similarity between patients’ sequences. 3. Pattern explorer: Extracting patterns of post-LVAD
sequential AEs in each group using Markov Molding [4].
Death
Cardiac Arrhythmia
Bleeding
Device Malfunction
Explant
Explant: Transplant
Hemolysis
Hepatic Dysfunction
Hypertension
Infection
Neurological Dysfunction
Renal Dysfunction
Respiratory Failure
REXP
Right Heart Failure
Fig. 3: Color code for 15 types of AEs and final outcomes
B. Hierarchical clustering
The goal of clustering is to identify clinically meaningful
groups of patients with relatively similar sequences of post-
LVAD AEs.
1) Defining the measure of dissimilarity: A distance ma-
trix, d, comprised of distances between each pair of patient
sequences was defined as:
d(Pn, Pm) = |Pn|+ |Pm| − 2LCS(Pn, Pm) (2)
where, |Pn| and |Pm| are the lengths of the sequences for
patients of Pn and Pm, respectively; LCS(Pn, Pm) is the
Longest Common Subsequence between Pn and Pm, as for-
mulated below:
LCS(Pn, Pm) = max{|l| : l ∈ SB(Pn, Pm)} (3)
Here, SB(Pn, Pm) is a set of all common subsequences
between Pn and Pm and |l| is the length of common sub-
sequence. A subsequence is a secondary sequence derived
from another (primary) sequence by deleting some or no
elements while maintaining the same order of the remaining
elements of the primary sequence. A common subsequence is
a subsequence that is common to both Pn and Pm. As an
example, the only common subsequence between the P1 , P2,
shown in Fig. 4, is the subsequences of (Bleeding)-(Infection).
Thus, in this example, the LCS is 2 and d(P1,P2) is 3 which
means by 3 movements (deletions of respiratory failure and
death from P1’s sequence and insertion a bleeding AE to P1’s
sequence) P1’s sequence becomes similar to P2’s sequence.
Infection
Respiratory 
Failure
DeathBleeding
Bleeding Bleeding
𝐿𝐶𝑆(𝑃1,𝑃2) = 2 
𝑑(𝑃1,𝑃2) = 4+3-2×2= 3
𝑃1
𝑃2 Infection
Fig. 4: An example of computing dissimilarity score between
two patients’ sequences.
2) Defining linkage method for hierarchical clustering:
After forming dissimilarity matrix of AE sequences, they
were clustered using bottom to top hierarchical clustering
with Ward linkage. Hierarchical clustering merges sequences
with lowest distance, d into a single group, and updates the
distance matrix for the newly merged group and remaining
patients. This merging process repeats using Ward’s method
in which groups of patients with lowest post-merging in-group
variance (sum of squares) are merged until all patients are
in one group. The Ward linkage distance between clusters is
computed using Lance–Williams recurrence algorithm [36].
Briefly, considering two clusters of Ci and Cj , the distance
between new cluster Cij (= Ci ∪ Cj) and remaining clusters
such as Ck is formulated as follows [36]:
D(ij,k) = αiD(ik) + αjD(jk) + βD(ij) + γ|D(ik) −D(jk)|
(4)
Here, D(ij,k) is the distance between new cluster Cij and
cluster Ck. Lance–Williams coefficients α, β, and γ are
different for various linkage methods and are defined for Ward
linkage as follows:
4αz =
|z|+ |k|
|i|+ |j|+ |k| , z = i, j
β = − |k||i|+ |j|+ |k|
γ = 0
(5)
Here, |.| indicates absolute value, and i, j, and k are
numbers of patients in each cluster.
3) Define criteria for choosing a number of clusters: The
clustering algorithm was implemented to maximize similarity
between sequences within a group (internal validation), and
minimize similarity between groups (external validation).
Internal validation (the within-group similarity) was per-
formed by extracting the most common subsequences and
their support values. This is the proportion of sequences in a
group that contain that specific subsequence and ranges from
0 to 1 (0% to 100%). The most common subsequences were
extracted from AE sequences by applying a prefix-tree-based
search algorithm using “TraMineR” package from R [37,38]. It
should be noted that this algorithm computes the support value
for a given subsequence by including all longer sequences
containing that subsequence. For instance, patients with the
subsequence of (Infection)-(Bleeding) are counted among the
patients with the subsequence of (Infection).
External validation (the between-groups dissimilarity) was
performed by identifying the subsequences that best differ-
entiate two groups of patients’ sequences using the Pearson
Chi-square test (p-value of ≤ 0.01).
Step-wise evaluation of clustering: The clustering evaluation
for choosing the number of groups (n) started with evaluating
the two-cluster solution (n= 2) and evaluation was continued
for bigger numbers of groups until both internal and external
criteria were satisfied for all the groups. At each step of
clustering evaluation, n was increased by 1; only one group
was divided into two new groups (G1 & G2) and their qualities
(high internal similarity and low external similarity) were
evaluated. First, external validation was checked between the
G1 and G2. If the external criteria were satisfied, internal
validations will be checked for each of the G1 and G2. If
any of G1 or G2 satisfied the internal validation, it was
considered as a qualified group, otherwise it was considered as
an unqualified group that needed to be split into sub-groups
with more similar sequences in the later steps of clustering
evaluation (bigger values of n).
Interactive visualization evaluation: To help visualize the
composition of AEs within each group (or sub-group), a
histogram was constructed using the same color coding from
Fig. 3. in which the proportions of each category of AE was
plotted for each position in the sequence. Fig. 5 provides the
histogram for the aggregate of all the 13,192 sequences of AEs
over their chronological positions in the sequences. The first
column of the graph, AE1, presents the proportions of various
types of AE that patients experienced as their first AEs (the
first element of the sequences of AEs), the second column for
the second AEs, and so forth, through the thirty sixth AE.
The uniformity of the distribution in the first set of columns
of the histogram (e.g. AE1 through AE20) is contrasted with
the heterogeneity of the subsequent columns. This reflects the
increasing diversity of AE’s as there is a decreasing number
of patients with longer sequences. For instance, there is only
one patient with a sequence of 36 AEs - the last AE being
death (yellow). This type of visualization is helpful to get a
general quick view of the distribution of AEs in a cluster of
patients.
𝑨𝑬𝟏 𝑨𝑬𝟑𝟔
0%
100%
Fig. 5: The proportions of various types of AE in all the 13,192
sequences of AEs in this study for temporally ordered AEs of
patients sequences (see Fig. 3. for color coding).
The final clusters were evaluated by our clinical experts to
determine the reasonableness of the clusters.
C. Markov Chain Models of AEs
Following clinical confirmation of the results of hierarchical
clustering, patterns of AEs for each group (cluster) were
analyzed using Markov modeling (MM). This has been shown
to be a useful tool to model repetitive events, where the timing
and the order of events are important [39]. For instance, the
transition of bleeding to infection can be considered different
if bleeding occurred as the 1st AE followed immediately by
infection, (Bleeding1)-(Infection2), versus bleeding occurred
as the 2nd AE, and then infection occurred, (Bleeding2)-
(Infection3). Accordingly, the transitions between sequential
AEs were assessed for likelihood of transitions as a function
of the chronological position in the sequence of AEs. As this
is the first attempt to model the sequential AEs after LVAD
implant, it was preferred to start with a simple solid model
such as the first-order Markov chain. MM was defined for a
sequence of AE1, AE2, AE3,... for discrete points of time:
1, ..., n was defined as follows:
P (AEn+1 = ae | AE1 = ae1, AE2 = ae2, ...., AEn = aen)
=
P (AEn+1 = ae | AEn = aen)
(6)
where ae was an AE from 15 different types of AE that could
occur in various orders in a sequence of AEs. The above
formula assumes that the probability of transitioning to the
next state, AEt+1, depends only on the present state, AEt.
Another assumption of MM is homogeneity, which assumes
all patients in the same state have the same risk of transition.
MM considers each types of AE as unique Markov state,
and transitions between states as events. As an example, a se-
quence of (Bleeding1)-(Infection2)-(Death3) was represented
5as (Bleeding1 → Infection2) ⇒ (Infection2 → Death3) that
includes 2 events presenting 2 transitions between 3 states/AEs
in the sequence. It also shows the transitivity relation between
2 events as the target state in the first event, Infection2, is
the source state in the second event. A transition matrix was
formed by computing transition probabilities between each
pair of states/AEs from all the sequences of AEs in each group.
Then, chains of events were extracted from the transition
matrix by connecting events that have transitivity relations.
Finally, thresholding of the extracted chains was performed,
based on the distributions of transition probabilities and fre-
quency of occurrence to eliminate the “noise” of numerous
infrequent or rare transitions. The thresholds were chosen
subjectively as 0.1 for transition probability and between 30
to 50 for frequency of occurrences, respectively, to achieve a
compromise between reducing noise versus over-simplifying
the resulting collection of MMs.
III. RESULTS
This study was performed with data from INTERMACS for
13,192 patients with advanced heart failure who underwent
continuous flow LVAD implant between 2006 and 2015. A
total number of 58,575 AEs, including 15 various types of
AE, were included in this study. Table. I summarizes the 15
types AEs and final outcomes, and indicates that “Bleeding”,
“Infection”, and “Cardiac Arrhythmia” are the most common
AEs.
The time of recorded AEs ranged between 0 (at the time
of implant) and 87 months (7.25 years) after LVAD implant
with mean of 9.95 months. A great proportion of AEs (81%
of total AEs) occurred within the first 18 months after LVAD
with the peak of AEs (27%) during the first month.
TABLE I: Frequency of Various Types of Events, Including
AEs and Final Outcomes, and Their Percentages of the Total
Number of Events. The Cells in the Table That Contains the
Final Outcomes Including “Death”, “Explant”, and “Explant:
Transplant” Are Highlighted in Light Orange Color.
Event Frequency Percent
Bleeding 12,877 22.0
Cardiac Arrhythmia 6,361 10.9
Device Malfunction 3,726 6.3
Hemolysis 797 1.4
Hepatic Dysfunction 850 1.4
Hypertension 701 1.2
Infection 13,399 22.9
Neurological Dysfunction 3,873 6.6
Renal Dysfunction 2,248 3.8
Respiratory Failure 3,614 6.2
REXP (RVAD explant) 92 0.1
Right Heart Failure 747 1.3
Death 3,675 6.3
Explant 1,819 3.1
Explant: Transplant 3,796 6.5
Total recorded events 58,575 100.0
A. Sequences of AEs
The length of AE sequences ranged from 1 to 36, however
94% of the sequences were less than or equal to 10. The
distribution of lengths ≤15 are provided in Fig. 6. (Lengths
16-32 were very rare, <1%, and therefore not shown).
Fig. 6: length of AE sequences from 1 to 15. (Length of 16-32,
not shown, were rare < 1%.
B. Hierarchical Clustering
Fig. 7 shows the distribution of dissimilarity scores between
AE sequences, which is left-skewed. The min/max of scores
were 0/53 with the mean of 10 and the median of 8. The
numbers of dissimilarity scores less than 2 and greater than
22 were negligible (≈0%).
Fig. 7: The dissimilarity scores distribution of all the sequences
of AEs
The result of hierarchical clustering is presented as a
dendrogram, shown in Fig. 8(a), which depicts the taxonomic
relationship between clusters formed at each level of grouping.
The bottom of the dendrogram represents all the patients’
dissimilarity scores, which is a dense dark area because of the
large number of patients. Moving from bottom to top of the
dendrogram, one cluster is formed at each level of hierarchical
clustering by grouping two sub-clusters until, at the top of the
dendrogram, all patients are in a single group. The y axis,
“Height”, represents the dissimilarity between clusters (groups
of patients) at that level of the tree, which is measured using
Ward linkage.
The eventual partitioning of the dendrogram was based
on the three criteria: the internal validation (within-group
similarity), external validation (between-groups dissimilarity),
and clinical interpretation. This was performed iteratively by
“cutting” the dendrogram horizontally. An example is shown
in Fig. 8(a) in which a horizontal cut results in two groups (G1
and G2). The first group includes 862 patients (7% of total
6G1 G2
(a) Cutting the dendrogram into the two clusters.
G1 G2
(b) A regression tree plotting distributions of various types of AE over
temporally ordered AEs in patients’ sequences.
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(c) Internal validation: support numbers for most common subse-
quences in two new-formed clusters.
(d) External validation: the first four discriminative sub-
sequences between G1 and G2. +/- determines the sign
of Pearson’s residual.
Fig. 8: First step of step-wise cluster evaluation: evaluation of the two-cluster solution
patients), and the second group that includes 12,330 patients
(93%). Their corresponding histograms (similar to Fig. 5) are
provided in Fig. 8(b), in which the proportions of various
types of AE are temporally ordered. Visual inspection of the
histogram corresponding to G1 reveals an obvious dominance
of the Bleeding AE (red color). This also implies a degree of
similarity of patients in this group. By contrast, the histogram
corresponding to G2 does not present any single dominant AE.
This is understandable since this group is comprised of a much
larger proportion of the total number of patients (93%). Thus,
the patients in the second group are not similar and require
further stratification.
Fig. 8(c) represents the support values of the five most
common subsequences in these two groups. In the first group
(G1), the unary sequence (Bleeding) and the binary sequence
(Bleeding)-(Bleeding) are the most common, both with support
value of 1, indicating that 100% of patients in this group
had a minimum of two bleeding AEs in their sequences. The
next most common sequences were found to be (Bleeding)-
(Bleeding)-(Bleeding) and (Bleeding)-(Bleeding)-(Bleeding)-
(Bleeding), with support values of 0.98 and 0.73. It was
concluded that the sequences in the first group all shared com-
mon subsequences, indicating high within-group similarity. In
contrast, the maximum support value for the second group
(G2) was approximately 50% corresponding to the (Infection)
subsequence. This indicated low similarity within this group,
and hence does not pass the internal validation.
As a final test, Fig. 8(d) shows the external validation in
which subsequences which best discriminate sequences of the
two groups via Pearson Chi-square test. The table shows the
first four most discriminative subsequences, in which the plus
(+) and minus (-) sign indicates that the observed frequencies
of the subsequences were higher (+) or lower (-) than equally
distributed frequencies. Here, p-values below 0.05 were taken
to indicate discrimination between groups. The subsequence of
(Bleeding)-(Bleeding)-(Bleeding) was the most discriminating
subsequence with p-value of 0.01 and support percentage for
G1 greater than 98%. All of the remaining discriminative sub-
sequences consisted of at least two bleeding AEs, emphasizing
that multiple bleeding AEs was responsible for differentiating
G1 from G2. Accordingly, it was concluded that the groupings
were externally validated.
7In summary, the initial two-cluster solution passed the
external validation, but only G1 passed the internal validation.
However, the second group which includes the remaining
93% of patients required further subdivision. This was accom-
plished in a similar manner, by bisecting the dendrogram at a
lower level, effectively separating the second group into two
sub-groups of 6,168 and 6,162 patients. This was followed
by the same process to evaluate the external and internal
validation. This procedure was repeated until all the resulting
groups passed validation, resulting in a final number of seven
groups (summarized in Table. II). For convenience, each of
the seven groups was given a mnemonic name based on
visual inspection of the histogram including: GRP1: “Recur-
rent bleeding”, GRP2: “ Trajectory of device malfunction &
explant”, GRP3: “ Infection”, GRP4: “Trajectories to trans-
plant”, GRP5: “ Cardiac arrhythmia”, GRP6: “Trajectory of
neurological dysfunction & death”, and GRP7: “ Trajectory of
respiratory failure & renal dysfunction & death”. For example,
this histogram of GRP1 reveals an obvious dominance of
the Bleeding AE (red color), and was therefore given the
name “Recurrent Bleeding.” In a similar fashion, G2 revealed
a dominance device malfunction (forest green) and explant
(lime green.) Since the two are always related sequentially,
this group was named “Trajectory of device malfunction &
explant.”
Fig. 9 demonstrates clustering results through a regression
tree. There is histogram associated with each of the groups;
the ordinate of which reflecting the proportion of each color-
coded AE type (from 0% to 100%) and abscissa reflecting
the location in the respective sequences. Since each group
has a unique maximum length, this is reflected in the varied
width of these plots. Each of these groups were assigned a
descriptive title that reflected the dominant AE or AEs therein.
For instance, the dominant colors in the GRP2 plot are yellow
green (representing device malfunction) and spurious green
(representing Explant outcome). Sequence analysis for GRP2,
similar to sequences analysis for GRP1 in Fig. 8(c)&(d), re-
veals that 1,097 out of 1,193 patients who experienced device
malfunction eventually had the device explanted, indicating
the temporal pattern (subsequence) of (Device Malfunction)-
(Explant). The sequence analysis was performed for each of
the seven groups.
Table. II provides statistics of each patient’s group. GRP3
and GRP4 had the highest number of patients and AEs by
having 26% and 25% of total number of patients, respectively,
and 27% and 17% of total recorded AEs, respectively, in this
study. On the other hand, GRP1 had the lowest number of
patients, 7% of the total number of patient (862 patients),
while they had 14% of total AEs. In addition, patients in
GRP1 had the greatest number of AEs with average number
of 9.73 AEs, and minimum and maximum numbers of 3 and
36 AEs. The average numbers of AEs in other groups were
≤5 and minimum numbers of AEs were 1. Columns of 6
and 7 of Table. II shows information related to the time of
AEs occurrences measured by the months after the LVAD
implants. The distributions of post-LVAD time (month) of AEs
occurrences were skewed to the right in all the groups as the
means were greater than the medians. The average time of AEs
Fig. 9: Regression tree showing groups formed at each step
of hierarchal clustering. Groups are split to smaller groups
until both internal and external criteria are satisfied. Groups
are numbered based on the steps in which they are formed.
occurrences were less than 13 months in all the groups and the
median time were less than 7 months. AEs of GRP7 occurred
at the earliest post-LVAD time by average of 6.06 months
after LVAD and median of 1 month after LVAD. The last
two columns of Table. II presents information related to the
time span of patients’ AEs (time of last AE - time of first AE)
measured in month. The distributions of time span of patients’
AEs were also skewed to right indicating higher number of
patients experienced AEs in a short time span. GRP1 had the
longest time span of AEs by average of 19.48 months between
the first AE and last AE, while, the GRP6 and the GRP7 had
the shortest time span by average of approximately 6 months
and median of 1 month.
C. Markov Chain Models of AEs
The following sections presents results of Markov modeling
(MM) within each of the groupings of patients presented
above. The chains of transitions between AEs are presented
with the graphs in which the size of the circles represent
the frequency of AEs at each position in the chain and the
thickness of the arrows reflecting the frequency of each AE
that are followed by the subsequent AE.
8TABLE II: Summary of Statistical Information Related to Groups Resulted from Hierarchical Clustering.
Number of AEs AEs post-LVAD time (month) † AEs time span (month) ††
Number of patients (*) Number of AEs (**) Min/Max Mean Median Mean Median Mean Median
GRP1:Recurrent bleeding
862 (≈7%) 8,388 (≈14%) 3/36 9.73 9 12.55 7 19.48 16
GRP2:Trajectory of device malfunction & explant
1,591 (≈12%) 7,049 (≈12%) 1/21 4.43 4 11.19 6 9.89 4
GRP3:Infection
3,438 (≈26%) 15,771 (≈27%) 1/31 4.59 3 11.31 6 10.25 4
GRP4:Trajectories to heart transplant
3,302 (≈25%) 10,093 (≈17%) 1/22 3.06 3 7.98 5 7.31 4
GRP5:Cardiac arrhythmia
1,275 (≈10%) 5,715 (≈10%) 1/22 4.48 3 8.63 3 9.48 4
GRP6:Neurological dysfunction & death
1,616 (≈12%) 5,911 (≈10%) 1/28 3.66 3 9.55 5 6.42 1
GRP7:Trajectory of respiratory failure & renal dysfunction & death
1,108 (≈8%) 5,648 (≈10%) 1/18 5.10 5 6.06 1 5.78 1
* % of the total 13,192 patients in this study
** % of the total 58,575 recorded AEs in this study
†AEs post-LVAD time is based on the month after LVAD implant (0 post-LVAD month means AE occurred at the time of LVAD implant)
†† AEs time span = time of the last AE (post-LVAD month) - time of first AE (post-LVAD month)
1𝑠𝑡 2𝑛𝑑 3𝑟𝑑 4𝑡ℎ 5𝑡ℎ 6
𝑡ℎ 7𝑡ℎ 8𝑡ℎ 9𝑡ℎ 10𝑡ℎ 11𝑡ℎ 12𝑡ℎ 13𝑡ℎ
Bleeding Infection
Fig. 10: MM of GRP1: Recurrent bleeding (n= 862 patients)
• GRP1: Recurrent bleeding
All the 862 patients in GRP1 had at least two bleeding
AEs, and among them, 98% (847 patients) had at least three
bleeding AEs. The Markov chain for GRP1, shown in Fig.
10 is characterized by a long sequence of recurrent bleeding
AE’s (red circles), with a limited amount of branching
involving an intermediate infection AE (blue circles). The
frequencies of transitions depicted by the thickness of the
arrows is seen to diminish progressively along the chain
over the time. For example, the transition frequency for
the 1st through 5th bleeding exceeded 300; but beyond the
5th bleeding event, the frequency reduced to the range 100-
250. This analysis revealed that the probability of recurrent
bleeding exceeded 50% for all instances up to the 13th
AE. The transitions probabilities from infection AEs to
bleeding AEs were 50% to 65%, while from bleeding AEs
to infection AEs were 14% to 18%.
• GRP2: Trajectory of device malfunction & explant.
75% of 1,591 patients in GRP2 experienced a device
malfunction and 94% had Explant as their final outcome.
The Markov chain for GRP2 (Fig. 11) was found to be
much more diverse than the chain for GRP1. Multiple
paths involving device malfunction (dark green) were found,
although the terminal event was most commonly (>50%)
1𝑠𝑡 2𝑛𝑑 3𝑟𝑑 4𝑡ℎ
Bleeding
Infection
Cardiac Arrhythmia
Device Malfunction
Explant
Fig. 11: MM of GRP2: Trajectory of device malfunction &
explant (n= 1,591 patients)
device explant (light green). Only a small number of patients
in this group (n=111, approximately 7%) experienced device
explant as the initial, isolated AE (indicated by the small
light green node at the bottom of the 1st column of Fig.
11). The majority of patients for which device explant was
recorded was preceded by another AE, most commonly
bleeding and infection (probability between 20-30%). There
were also about 18% and 19% probabilities of recurrent de-
91𝑠𝑡 2𝑛𝑑 3𝑟𝑑 4𝑡ℎ 5𝑡ℎ 6𝑡ℎ 7𝑡ℎ 8𝑡ℎ 9𝑡ℎ 10𝑡ℎ 11𝑡ℎ
Bleeding InfectionCardiac Arrhythmia Respiratory FailureExplant: Transplant
Fig. 12: MM of GRP3: Infection (n= 3,438 patients)
vice malfunction as the 2nd AEs or the 3th AEs, respectively.
The frequency of transition from Infection as the 2nd AE to
Explant was 21%, but with no reported device malfunction
AE (n=211, the spurious green circle in the 1st column).
• GRP3: Infection
The Markov chain for GRP3 (Fig. 12) is characterized by a
long sequence of infection AEs (blue circles), corresponding
to a total number of 6,462 recorded infection AEs for
3,438 patients in GRP3, with a limited amount of branching
involving an intermediate bleeding AE (red circles). This
analysis revealed that the probability of recurrent infection
ranged from 34% to 49%. The frequencies of recurrent
infection AEs depicted by the thickness of the arrows is
seen to diminish progressively along the chain. For example,
the transition frequency for the 1st through 4th infection
AEs ranged 300-420; but beyond the 4th infection event,
the frequency reduced to the range of 50-300. The transition
probabilities from bleeding to infection were 39% to 45%,
while from infection to bleeding were less than 18%. There
were also 285 patients (8%) who received a heart transplant
after experiencing an infection AE (represented by the dark
green circle in the 2nd column in Fig. 12). There were also
transitions from cardiac arrhythmia and respiratory failures
as the 1st AEs to infection as the 2nd AEs.
• GRP4: Trajectories to transplant
The Markov chains for GRP4 (Fig. 13) represents AE
trajectories of 3,302 patients who ended in receiving a
heart transplant. The majority of patients who revived heart
transplants was precede by various types of AE, most
commonly bleeding, infection, and cardiac arrhythmia. Only
970 patients (29%) in this group received a heart transplant
as the initial, isolated event (the dark green circle in the
first column of Fig. 13). AE trajectories to heart transplants
from some specific types of AE like bleeding, infection,
or cardiac arrhythmia were more likely than other types of
AE like neurological dysfunction AE or device malfunction
AE. For instance, 520 patients who experienced only one
AE and then received a heart transplant were preceded
by mostly bleeding or cardiac arrhythmia (cumulative 388
patients), and minimally by neurological dysfunction or
device malfunction (cumulative 132 patients).
• GRP5: Cardiac arrhythmia
Fig. 14 represents a chain of recurrent cardiac arrhyth-
mia AEs (orange circles) in GRP5 (1,275 patients), with
a limited amount of branching involving an intermediate
infection AE (blue circles). The frequency of transitions
depicted by the thickness of the arrows is seen to diminish
1𝑠𝑡 2𝑛𝑑 3𝑟𝑑 4𝑡ℎ 5𝑡ℎ
Bleeding
Infection
Device Malfunction
Cardiac Arrhythmia
Explant: Transplant
Neurological Dysfunction
Fig. 13: MM of GRP4: Trajectories to transplant (n= 3,302
patients)
progressively along the chain. As an example, 919 patients
in GRP5 (72%) experienced cardiac arrhythmia as 1st AE
and only 242 of them experienced cardiac arrhythmia as
the 2nd AE too; beyond the 2nd AE the frequency gradually
decreased to 71 for cardiac arrhythmia as the 6th AE. The
probability of transitions for recurrent cardiac arrhythmia
AEs were between 34% to 49% over the time. There were
also transitions between cardiac arrhythmia and infection
with probabilities from 16% to 36%.
1𝑠𝑡 2𝑛𝑑 3𝑟𝑑 4𝑡ℎ 5𝑡ℎ 6𝑡ℎ
Bleeding InfectionCardiac Arrhythmia
Fig. 14: MM of GRP5: Cardiac arrhythmia (n= 1,275 patients)
• GRP6: Trajectory of neurological dysfunction & death
The Markov chain of GRP6 (Fig. 15) shows the trajectory
of 1,616 patients who died (yellow circles) after suffering
from neurological dysfunction AEs (purple circles). The
rate of death for patients who suffered from neurological
dysfunction AEs as the 1st AE trough 3th AE ranged from
27% to 39%. The majority of patients for which neurological
dysfunction AE was recorded was preceded by other types
of AE, most commonly bleeding and infection. Only a small
number of patients in GRP6 (n=229, approximately 14%)
died with no reported AEs (the yellow circle in the 1st
column of Fig. 15). There were also a small number of
patients who died after one or recurrent infection AEs with
no recorded neurological dysfunction AE (thin blue arrows
from blue circles to yellow circles).
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1𝑠𝑡 2𝑛𝑑 3𝑟𝑑 4𝑡ℎ
Respiratory Failure
Death
Bleeding
Infection
Neurological Dysfunction
Fig. 15: MM of GRP6: Trajectory of neurological dysfunction
& death (n= 1,616 patients)
• GRP7: Trajectory of respiratory failure & renal dysfunc-
tion & death
The Markov chain of GRP7 (Fig. 16) illustrates two different
AE trajectories to death. One main trajectory represents
929 patients who died after suffering from respiratory
failure (934 recorded respiratory failure AE) and/or renal
dysfunction AEs (712 recorded renal dysfunction AEs)
with transition probabilities between 22% to 44%. It also
revealed that patients with reported respiratory failure and
renal dysfunction were preceded by other types of AE,
most commonly by infection AE and bleeding AE. The
transition probabilities from renal dysfunction or infection
to respiratory failure ranged from 32% to 36%. Another
trajectory of this group presents 179 patients who died after
suffering from one or recurrent bleeding AEs with transition
probabilities from 19% to 24%.
1𝑠𝑡 2𝑛𝑑 3𝑟𝑑 4𝑡ℎ 5𝑡ℎ
Respiratory Failure
Death
Bleeding
Infection
Renal Dysfunction
Fig. 16: MM of GRP7: Trajectory of respiratory failure &
renal dysfunction & death (n= 1,108 patients)
IV. DISCUSSION
This is the first study to explore patterns of sequential
AEs and their related final outcomes in patients with ad-
vanced heart failure who received an LVAD implant. The
results of our analysis revealed previously-unknown or under-
appreciated patterns of adverse events in LVAD patients, and
their relationships with final outcomes, as presented in Table.
III. These trajectories can be used as the basis for personalized
medical management of the LVAD patient: by identifying
developing patterns of AE’s and therefore intervening with
evasive treatment.
Patients were not equally distributed among the groups that
resulted from clustering. As an example, GRP1 (Recurrent
bleeding) include small group of patients (less than 1000)
who experienced greatest numbers of AEs (with a median
of 9 AEs). While, each of GRP3 (Infection) and GRP4
(Trajectories to transplant) included more than 3000 patients
with the median number of 3 AEs. The imbalanced number of
patients in the groups implies high incidence of specific AE
patterns among the patients with LVAD that seek more clinical
attention for future enhancement of LVAD outcome.
The time of occurrence following implant is very important
to the analysis of AEs. It is highly valuable for physicians
to know how many days or months after LVAD implant AEs
are likely to occur or how quickly a series of AEs may occur
for a patient. The time analysis of AE sequential patterns
(Table. II) indicates various timing characteristics among the
groups. For instance, AEs in the GRP7 with respiratory and
renal failure occurred in the immediate months after LVAD
implant with median time of 1 month after LVAD implant
reflecting typical post-operative timing of these events. This
is in contrast to AEs in the bleeding group (GRP1) with
median time of 9 months after LVAD implant, more typical of
onset of gastrointestinal bleeding. This analysis also revealed
differences in time span over which AEs occurred between
groups. For example, AEs for patients with neurological
events (GRP6) occurred over a short period of time (median
time span of 1 month) contrasted with GRP5 patients
whose AEs spanned a median of 4 months. These different
timing characteristics of AE sequential patterns may have
implications in guiding post-LVAD medical interventions or
preventative measures.
Challenges & Limitations & Future work
The first challenge encountered in this study was related to
data preprocessing including choosing a right population of
patients and AEs. This part of study was an iterative process,
involving feedback from clinicians about medical interpreta-
tion of the results. As an example, it was decided to exclude
AEs after the explant of the first LVAD as patterns of AEs and
clinical decisions and therapies for patients with more than
one device are unique and need to be studied separately. Also,
the choice of criteria to evaluate clustering results and decide
about the number of groups was another challenge. Zhang et
al. [4] used Silhouette values to determine cluster number and
support values for internal evaluation of clustering. However,
the number of patients in this study (13,192 patients) was more
than 10 times greater compared with the number of patients
in [4] (1,576 patients). Thus, considering only support values
was inadequate. It is obvious that high numbers of groups will
result in increasing similarity of patients within each group;
however, the number of groups should be limited to preserve
the clinical utility of the results. This was the motivation to
the step-wise clustering evaluation that was implemented that
considers both within-group similarity and between-groups
dissimilarity criteria.
Markov models in this study considered the order of occur-
rences for AE transitions in patient’s sequences. For instance,
the transition from bleeding as the first AE to infection as
the second AE was considered different from transition from
bleeding as the fifth AE to infection as the sixth AE. Thus,
the probabilities of transitions were evaluated by considering
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TABLE III: Summary of Clinical Insights of the Groups Resulted from Hierarchical Clustering.
GRP1:Recurrent bleeding
Patients who experienced recurrent bleeding AEs after LVAD. Recurrent occurrences of various types of bleeding such as gastrointestinal bleeding is commonly
reported in clinical studies of patients who receive an LVAD [7,9,13]
GRP2:Trajectory of device malfunction & explant
Patients who had device malfunction and commonly had their LVADs removed (explanted). This trajectory was found to be preceded by the two types of AEs
including infection and bleeding. Two others, less common, trajectories within GRP2 were 1. patients who had an explant without device malfunction and 2.
patients who had a device malfunction without ending in explant. In clinical literature, device malfunction is defined as failure of one or more parts of LVAD
that cause the inability to maintain adequate circulatory support. Device malfunction might be deadly or could be solved by replacing the device (explant)
[40,41]. It is important to note that within INTERMACS patients there may be some who had serious pump malfunction such as internal thrombosis, but
the patient was not considered a candidate for pump exchange and the LVAD may have been simply turned off.
GRP3:Infection
Patients who suffered mostly from infection AEs. The most recent INTERMACS annual report indicated infection as the most frequent AE after bleeding
during the first three months and the most common AE thereafter [3].
GRP4:Trajectories to heart transplant
Patients who received a heart transplant and the pump was explanted as part of the procedure. AE trajectories to heart transplant were mostly consisted of
bleeding AE, infection AE, and cardiac arrhythmia AE. In practical terms these AEs resulted in an upgraded listing for cardiac transplant resulting in a
higher likelihood of achieving a heart transplant. It is not uncommon for LVAD complications to drive more urgent listing status of a candidate and this
analysis conforms that strategy. The most recent INTERMACS annual reports indicated slightly more than 30% of heart transplant candidates who received
continuous-flow LVAD received a heart transplant [3,42].
GRP5:Cardiac arrhythmia
Patients who experienced one or recurrent cardiac arrhythmia AEs after LVAD implant that accompanied mostly with infection AEs and bleeding AEs.
Patients with ventricular arrhythmias tend to have recurrent episodes of these rhythm disturbances one they begin to manifest them.
GRP6:Neurological dysfunction & death
GRP6 trajectory is supported by clinical literature highlighting the high mortality in LVAD patients with neurological events especially with hemorrhagic
strokes [11,12,19,20]
GRP7:Trajectory of respiratory failure & renal dysfunction & death
GRP7 trajectory is predominated by both respiratory failure AEs and renal dysfunction AEs that ended in death although some of the trajectories also were
accompanied by a bleeding AE and an infection AE. The eighth INTERMACS annual report named renal dysfunction and chronic pulmonary disease among
the non-cardiac system commodities that impact the LVAD survival rate [3].
where in the patient’s sequence transitions occurred. This
temporal constraint is very useful since AEs have a different
effect on LVAD final outcome when they occurred in imme-
diate succession as compared to a sequence with a different
intermediate AE.
One main limitation of this study is related to the voluntary
collection and reporting of INTERMACS data. As an example,
some AEs like infection is a longitudinal AE that might last
for a while, but INTERMACS only records the occurrence of
AE without recording its duration. Another issue is that there
is no information regarding the order of concurrent AE (events
occurred at the same day). The problem was exacerbated by
the fact that this registry is comprised of contributions of over
100 centers, and hence involves differences in interpretation of
definitions, omissions, and data entry errors. As an example,
the ongoing change in the definition of right heart failure
(RHF) causes inconsistency between studies about analysis of
RHF, and therefore, reduces the confidence in results. Conse-
quently, it would be helpful to pull in expertise from field to
learn more about INTERMACS definitions and workflow of
data collection, to avoid bias in the future studies.
The time gaps between sequential AEs were not considered
in clustering and Markov modeling to minimize the diversity
of sequences. One solution that was evaluated was to segment
post-LVAD time, based on the critical points based on the
AEs distribution and physicians’ suggestions. This reduced the
maximum number of time points in the sequences from 36 to
7. However, it was not adequate to prevent enormously increas-
ing diversity. Further consolidating the timeline into short-term
and long-term could be another solution that requires some
iterative process to find an optimum. Adding time gaps will
also help concurrent AEs issue by considering basket of AEs
with 0 time gaps as one element in the sequence [43].
The existence of sequential post-LVAD AEs raises the
question of what causes patients to experience different AEs
patterns. Further research of post-LVAD AEs must seek to
include pre and post LVAD risk factors to improve the prog-
nostic value of this analysis. An accurate prediction of the
next AE (AEn+1) by considering previous AEs (AE1 to AEn)
would be another important contribution, and a valuable tool
for physicians to optimize treatment to minimize the risk of
future AEs.
V. CONCLUSION
This study, to the best knowledge of the authors, was
the first exploratory to discover sequential chains of AEs
following LVAD implant. Mining of the AE sequences of
13,192 patients with advanced heart failure derived from the
INTERMACS registry revealed the existence of seven groups
of sequential chains of AEs, each characterized by a dominant
AE or multiple AEs and occurring in a unique order. The
discovered chains of AEs disclose potential interdependence
between AEs and provide clinicians a valuable insight into
the patient oriented post-LVAD AEs evidence. It is hoped that
this analysis may support post-LVAD follow-up by alerting
medical providers of the likelihood of impending AEs - based
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on a combination of independent factors, and patterns of prior
AEs.
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